FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns valsartan pill obtained by pressing. A pill contains pharmacologically effective valsartan quantity, filler and fluffer. Weight ratio of valsartan to filler is 2:1 to 0.3:1. Weight ratio of valsartan to fluffer is 2.9:1 to 1:1. The pill includes over 30 mass % of filler. Preferable filler is monocrystallic cellulose. Preferable fluffer is crospovidone. The claimed pill has at least 1.2 times higher biological accessibility in comparison to the known valsartan-containing composition.
EFFECT: increased biological accessibility of valsartan-containing composition.
9 cl, 2 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID ORAL DOSAGE FORMS OF VALSARTAN | 2007 |
|
RU2453306C2 |
| VALSARTAN-BASE SOLID ORAL DOSING FORMULATIONS | 1997 |
|
RU2294743C2 |
| SOLID ORAL DOSED VALSARTAN-BASED FORMS | 1997 |
|
RU2203054C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| SOLID PERORAL DOSED OUT FORMS OF VALSARTAN | 2005 |
|
RU2361575C2 |
| USING RECEPTOR AT-1 ANTAGONIST OR RECEPTOR AT-2 MODULATOR IN TREATMENT OF DISEASES ASSOCIATED WITH INCREASE CONTENT OF AT-1 OR AT-2 RECEPTORS | 1999 |
|
RU2271809C2 |
| DIPHOSPHONIC ACID-CONTAINING COMPOSITIONS | 1999 |
|
RU2207860C2 |
| PHARMACEUTICAL COMPOSITION OF VALSARTAN | 2008 |
|
RU2487710C2 |
| COMBINATION OF AT LEAST TWO COMPOUNDS CHOSEN FROM GROUPS AT-RECEPTOR ANTAGONISTS OR INHIBITORS OF ACE (ANGIOTENSIN-CONVERTING ENZYME) OR INHIBITORS OF HMG-COA-REDUCTASE (BETA-HYDROXY-BETA-METHYLGLUTARYL-COENZYME-A-REDUCTASE) | 2001 |
|
RU2298418C2 |
| CEFUROXIMAXETIL-CONTAINING COMBINATIONS | 1999 |
|
RU2248794C2 |
